Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Aouba, A.
Right arrow Articles by Patri, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aouba, A.
Right arrow Articles by Patri, B.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2003; 42: 800-802
© 2003 British Society for Rheumatology

Letters to the Editor

Haemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab

A. Aouba1,3,, M. De Bandt1, E. Aslangul1, N. Atkhen2 and B. Patri1

1 Department of Internal Medicine and Rheumatology and
2 Unit of Haematology, Hôpital Européen Georges Pompidou and
3 Department of Haematology, Hôpital Necker-Enfants Malades, Paris, France

The first 10% of the full text of this article appears below.

SIR, Inhibitors of tumour necrosis factor {alpha} (TNF-{alpha}; monoclonal antibodies or soluble receptors) have proven their efficacy in the treatment of rheumatoid arthritis (RA) and are currently under investigation in other chronic inflammatory diseases. However, an increase in infectious complications is noticed with these molecules. We report an RA patient who developed haemophagocytic syndrome (HPS) while she was being treated with infliximab.

A 46-yr-old woman had suffered from seropositive RA (American Rheumatism Association criteria) since 1999. Despite active treatment with steroids, methotrexate and sulphasalazine, the disease remained active [disease activity score (DAS) >4.5]. Treatment with infliximab (3 mg/kg) was started in December 2000 with a good . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
H. Ideguchi, S. Ohno, K. Takase, H. Hattori, Y. Kirino, M. Takeno, and Y. Ishigatsubo
Successful treatment of refractory lupus-associated haemophagocytic lymphohistiocytosis with infliximab
Rheumatology, October 1, 2007; 46(10): 1621 - 1622.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
J. Ledingham, C. Deighton, and on behalf of the British Society for Rheumatology
Update on the British Society for Rheumatology guidelines for prescribing TNF{alpha} blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)
Rheumatology, February 1, 2005; 44(2): 157 - 163.
[Full Text] [PDF]